Baidu
map

Int J Clin Pract:非布司他治疗疑似COVID-19门诊患者的疗效

2021-07-15 MedSci原创 MedSci原创

近日,一项临床试验评估了非布司他(FBX)与羟氯喹(HCQ)对门诊中度症状的COVID-19感染患者的临床症状、实验室检查和胸部CT结果的影响,研究结果已发表于Int J Clin Pract。

近日,一项临床试验评估了非布司他(FBX)与羟氯喹(HCQ)对门诊中度症状的COVID-19感染患者的临床症状、实验室检查和胸部CT结果的影响,研究结果已发表于Int J Clin Pract。

研究纳入了COVID-19感染后的中度呼吸道疾病的成年门诊患者,将其1:1随机分配接受FBX或HCQ,为期5天。变量是住院需求、临床和实验室数据,包括发烧、咳嗽、呼吸频率、C-反应蛋白水平、入院时和治疗5天时的淋巴细胞计数。此外,入院时和开始治疗后14天对CT结果进行了评估。

 

结果,60名受试者被纳入研究,入院时患者有发热(66.7%)、咳嗽(87%)、呼吸急促(44.4%)、呼吸困难(35%)、CRP值升高(94.4%)和肺部受累(100%),FBX组和HCQ组之间差异不明显。两组患者在治疗5天后,发热、咳嗽和呼吸急促的症状都明显减轻,组间无明显差异。使用FBX和HCQ治疗14天后,肺部受累的平均百分比分别明显降低到7.3%和8%。在中度COVID-19感染的成人门诊患者中,FBX和HCQ在解决临床表现、实验室检查和肺部CT结果方面的疗效没有差异。

综上,该试验表明,FBX是作为HCQ的替代治疗COVID-19感染的方法,对HCQ有禁忌症或预防措施的患者可以考虑。

 

原始出处:

 

Lotfollah Davoodi, et al., Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. Int J Clin Pract. 2020 Nov;74(11):e13600. doi: 10.1111/ijcp.13600. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1721768, encodeId=8c781e2176870, content=<a href='/topic/show?id=852f9939eda' target=_blank style='color:#2F92EE;'>#非布司他#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99397, encryptionId=852f9939eda, topicName=非布司他)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd1133082510, createdName=dinorsor535, createdTime=Mon May 16 02:38:55 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932057, encodeId=3e71193205e8d, content=<a href='/topic/show?id=e7bd9e12736' target=_blank style='color:#2F92EE;'>#门诊患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97127, encryptionId=e7bd9e12736, topicName=门诊患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jun 01 19:38:55 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999619, encodeId=68ee9996192e, content=了解一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Thu Jul 15 05:00:42 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033030, encodeId=67cb103303085, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Jul 15 03:38:55 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1721768, encodeId=8c781e2176870, content=<a href='/topic/show?id=852f9939eda' target=_blank style='color:#2F92EE;'>#非布司他#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99397, encryptionId=852f9939eda, topicName=非布司他)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd1133082510, createdName=dinorsor535, createdTime=Mon May 16 02:38:55 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932057, encodeId=3e71193205e8d, content=<a href='/topic/show?id=e7bd9e12736' target=_blank style='color:#2F92EE;'>#门诊患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97127, encryptionId=e7bd9e12736, topicName=门诊患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jun 01 19:38:55 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999619, encodeId=68ee9996192e, content=了解一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Thu Jul 15 05:00:42 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033030, encodeId=67cb103303085, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Jul 15 03:38:55 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1721768, encodeId=8c781e2176870, content=<a href='/topic/show?id=852f9939eda' target=_blank style='color:#2F92EE;'>#非布司他#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99397, encryptionId=852f9939eda, topicName=非布司他)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd1133082510, createdName=dinorsor535, createdTime=Mon May 16 02:38:55 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932057, encodeId=3e71193205e8d, content=<a href='/topic/show?id=e7bd9e12736' target=_blank style='color:#2F92EE;'>#门诊患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97127, encryptionId=e7bd9e12736, topicName=门诊患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jun 01 19:38:55 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999619, encodeId=68ee9996192e, content=了解一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Thu Jul 15 05:00:42 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033030, encodeId=67cb103303085, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Jul 15 03:38:55 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 学医无涯

    了解一下~

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1721768, encodeId=8c781e2176870, content=<a href='/topic/show?id=852f9939eda' target=_blank style='color:#2F92EE;'>#非布司他#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99397, encryptionId=852f9939eda, topicName=非布司他)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bd1133082510, createdName=dinorsor535, createdTime=Mon May 16 02:38:55 CST 2022, time=2022-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1932057, encodeId=3e71193205e8d, content=<a href='/topic/show?id=e7bd9e12736' target=_blank style='color:#2F92EE;'>#门诊患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97127, encryptionId=e7bd9e12736, topicName=门诊患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Wed Jun 01 19:38:55 CST 2022, time=2022-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=999619, encodeId=68ee9996192e, content=了解一下~, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b7a31928393, createdName=学医无涯, createdTime=Thu Jul 15 05:00:42 CST 2021, time=2021-07-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1033030, encodeId=67cb103303085, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Thu Jul 15 03:38:55 CST 2021, time=2021-07-15, status=1, ipAttribution=)]
    2021-07-15 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

PLOS ONE :新冠病毒加剧了印度抗生素的滥用

印度新冠疫情加剧,已有超过 3000 万人感染,近40万人死亡,但专家认为,实际情况很可能要严重得多。与此同时,另一场公共卫生危机也出现了---那就是抗生素的广泛滥用。

世卫组织:强烈建议不要使用羟氯喹预防新冠肺炎

世卫组织指南制定专家组发布声明,强烈建议不要使用羟氯喹来预防感染新冠病毒。该药不再是研究重点,资源应集中在其他更有前途的药物上。该建议适用于所有未感染新冠病毒的个人,无论其是否接触过新冠病毒感染者。

NEJM:羟氯喹或羟氯喹与阿奇霉素联合治疗新冠肺炎效果不显著

研究结果不支持羟氯喹或羟氯喹与阿奇霉素联合使用治疗新冠肺炎

Nat Commun:曾经“炙手可热”的氯喹到底会如何影响新冠患者死亡率?

该研究表明,在新冠患者中,使用羟氯喹治疗与死亡率增加相关,而氯喹没有表现出益处。

Int J Antimicrob Agents:羟氯喹可显著降低COVID-19患者的病毒载量

氯喹和羟氯喹对SARS-CoV-2有效,并有报道对中国COV-19患者有效。本研究旨在评价羟氯喹对呼吸道病毒载量的影响。

NEJM:瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a对新冠肺炎住院患者无明显治疗作用

瑞德西韦、羟氯喹、洛匹那韦和干扰素β-1a在降低新冠肺炎患者死亡率、机械通气及住院时间方面均无显著效果

Baidu
map
Baidu
map
Baidu
map